癌症研究
脚手架
活性氧
吉西他滨
原位
化学
医学
药理学
癌症
生物化学
内科学
生物医学工程
有机化学
作者
Chao Wang,Jinqiang Wang,Xudong Zhang,Shuangjiang Yu,Di Wen,Quanyin Hu,Yanqi Ye,Hunter N. Bomba,Xiuli Hu,Zhuang Liu,Gianpietro Dotti,Zhen Nan Gu
标识
DOI:10.1126/scitranslmed.aan3682
摘要
Patients with low-immunogenic tumors respond poorly to immune checkpoint blockade (ICB) targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway. Conversely, patients responding to ICB can experience various side effects. We have thus engineered a therapeutic scaffold that, when formed in situ, allows the local release of gemcitabine (GEM) and an anti-PD-L1 blocking antibody (aPDL1) with distinct release kinetics. The scaffold consists of reactive oxygen species (ROS)-degradable hydrogel that releases therapeutics in a programmed manner within the tumor microenvironment (TME), which contains abundant ROS. We found that the aPDL1-GEM scaffold elicits an immunogenic tumor phenotype and promotes an immune-mediated tumor regression in the tumor-bearing mice, with prevention of tumor recurrence after primary resection.
科研通智能强力驱动
Strongly Powered by AbleSci AI